PTCT vs UNH

PTC Therapeutics maintains potential in rare diseases with key assets like Sephience (PKU) and gene therapy Upstaza. Analyst sentiment has notably improved with several price target upgrades post-Q4 2025 earnings, suggesting optimism despite the previous quarter's significant revenue and EPS miss. However, the recent withdrawal of the Translarna (DMD) New Drug Application due to FDA feedback is a ...

UnitedHealth Group (UNH) remains a healthcare titan, but its sheer scale and the highly regulated nature of its operations fundamentally limit its 10x growth potential within 3-5 years. The recent Optum Health operating loss of $278M in 2025 (compared to $7.77B income in 2024) is a significant concern, eroding the growth narrative that Optum once provided. Furthermore, the proposed 0.09% Medicare ...